223 related articles for article (PubMed ID: 21209961)
1. Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells.
Keren H; Donyo M; Zeevi D; Maayan C; Pupko T; Ast G
PLoS One; 2010 Dec; 5(12):e15884. PubMed ID: 21209961
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients.
Yannai S; Zonszain J; Donyo M; Ast G
PLoS One; 2019; 14(3):e0211602. PubMed ID: 30889183
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylserine increases IKBKAP levels in a humanized knock-in IKBKAP mouse model.
Bochner R; Ziv Y; Zeevi D; Donyo M; Abraham L; Ashery-Padan R; Ast G
Hum Mol Genet; 2013 Jul; 22(14):2785-94. PubMed ID: 23515154
[TBL] [Abstract][Full Text] [Related]
4. Sensory and autonomic deficits in a new humanized mouse model of familial dysautonomia.
Morini E; Dietrich P; Salani M; Downs HM; Wojtkiewicz GR; Alli S; Brenner A; Nilbratt M; LeClair JW; Oaklander AL; Slaugenhaupt SA; Dragatsis I
Hum Mol Genet; 2016 Mar; 25(6):1116-28. PubMed ID: 26769677
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylserine enhances IKBKAP transcription by activating the MAPK/ERK signaling pathway.
Donyo M; Hollander D; Abramovitch Z; Naftelberg S; Ast G
Hum Mol Genet; 2016 Apr; 25(7):1307-17. PubMed ID: 26769675
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Hervé M; Ibrahim EC
Neurobiol Dis; 2017 Jul; 103():113-122. PubMed ID: 28404519
[TBL] [Abstract][Full Text] [Related]
7. Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia.
Yoshida M; Kataoka N; Miyauchi K; Ohe K; Iida K; Yoshida S; Nojima T; Okuno Y; Onogi H; Usui T; Takeuchi A; Hosoya T; Suzuki T; Hagiwara M
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2764-9. PubMed ID: 25675486
[TBL] [Abstract][Full Text] [Related]
8. Familial Dysautonomia (FD) Human Embryonic Stem Cell Derived PNS Neurons Reveal that Synaptic Vesicular and Neuronal Transport Genes Are Directly or Indirectly Affected by IKBKAP Downregulation.
Lefler S; Cohen MA; Kantor G; Cheishvili D; Even A; Birger A; Turetsky T; Gil Y; Even-Ram S; Aizenman E; Bashir N; Maayan C; Razin A; Reubinoff BE; Weil M
PLoS One; 2015; 10(10):e0138807. PubMed ID: 26437462
[TBL] [Abstract][Full Text] [Related]
9. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia.
Anderson SL; Qiu J; Rubin BY
Biochem Biophys Res Commun; 2003 Jun; 306(1):303-9. PubMed ID: 12788105
[TBL] [Abstract][Full Text] [Related]
10. Loss-of-function of IKAP/ELP1: could neuronal migration defect underlie familial dysautonomia?
Naumanen T; Johansen LD; Coffey ET; Kallunki T
Cell Adh Migr; 2008; 2(4):236-9. PubMed ID: 19262150
[TBL] [Abstract][Full Text] [Related]
11. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia.
Axelrod FB; Liebes L; Gold-Von Simson G; Mendoza S; Mull J; Leyne M; Norcliffe-Kaufmann L; Kaufmann H; Slaugenhaupt SA
Pediatr Res; 2011 Nov; 70(5):480-3. PubMed ID: 21775922
[TBL] [Abstract][Full Text] [Related]
12. Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing.
Gold-von Simson G; Goldberg JD; Rolnitzky LM; Mull J; Leyne M; Voustianiouk A; Slaugenhaupt SA; Axelrod FB
Pediatr Res; 2009 Mar; 65(3):341-6. PubMed ID: 19033881
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia.
Hervé M; Ibrahim EC
Dis Model Mech; 2016 Aug; 9(8):899-909. PubMed ID: 27483351
[TBL] [Abstract][Full Text] [Related]
14. Olfactory stem cells, a new cellular model for studying molecular mechanisms underlying familial dysautonomia.
Boone N; Loriod B; Bergon A; Sbai O; Formisano-Tréziny C; Gabert J; Khrestchatisky M; Nguyen C; Féron F; Axelrod FB; Ibrahim EC
PLoS One; 2010 Dec; 5(12):e15590. PubMed ID: 21187979
[TBL] [Abstract][Full Text] [Related]
15. RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the
Ohe K; Yoshida M; Nakano-Kobayashi A; Hosokawa M; Sako Y; Sakuma M; Okuno Y; Usui T; Ninomiya K; Nojima T; Kataoka N; Hagiwara M
RNA; 2017 Sep; 23(9):1393-1403. PubMed ID: 28592461
[TBL] [Abstract][Full Text] [Related]
16. IKAP expression levels modulate disease severity in a mouse model of familial dysautonomia.
Dietrich P; Alli S; Shanmugasundaram R; Dragatsis I
Hum Mol Genet; 2012 Dec; 21(23):5078-90. PubMed ID: 22922231
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice.
Sinha R; Kim YJ; Nomakuchi T; Sahashi K; Hua Y; Rigo F; Bennett CF; Krainer AR
Nucleic Acids Res; 2018 Jun; 46(10):4833-4844. PubMed ID: 29672717
[TBL] [Abstract][Full Text] [Related]
18. Of splice and men: what does the distribution of IKAP mRNA in the rat tell us about the pathogenesis of familial dysautonomia?
Mezey E; Parmalee A; Szalayova I; Gill SP; Cuajungco MP; Leyne M; Slaugenhaupt SA; Brownstein MJ
Brain Res; 2003 Sep; 983(1-2):209-14. PubMed ID: 12914982
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia.
Cuajungco MP; Leyne M; Mull J; Gill SP; Lu W; Zagzag D; Axelrod FB; Maayan C; Gusella JF; Slaugenhaupt SA
Am J Hum Genet; 2003 Mar; 72(3):749-58. PubMed ID: 12577200
[TBL] [Abstract][Full Text] [Related]
20. Retina-specific loss of
Ueki Y; Shchepetkina V; Lefcort F
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29929962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
